Osimertinib (Tagressa) medical insurance reimbursement conditions

Osimertinib is an oral targeted therapy drug that is a third-generation epidermal growth factor receptor (EGFR) inhibitor. It is specifically designed to treat non-small cell lung cancer (NSCLC), especially those with advanced NSCLC patients with EGFR gene mutations.

Osimertinib medical insurance reimbursementlimit:1. Stage IB-IIIA non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation (NSCLC) patients must have previously undergone surgical resection, and the doctor will decide whether to accept adjuvant chemotherapy; 2.< /span>Has epidermal growth factor receptor (EGFR) exon19 deletion or exon21 (L858R< /span>) First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with substitution mutations; 3.Previous disease progression during or after treatment with EGFRtyrosine kinase inhibitors (TKI), and the presence of EGFR was confirmed by testing Treatment of adult patients with T790Mmutation-positive locally advanced or metastaticNSCLC.

As a targeted therapy drug, the mechanism of action of osimertinib is mainly to block the growth and spread of tumor cells by inhibiting the activity ofEGFRtyrosine kinase. Compared with first- and second-generation EGFR inhibitors, osimertinib has higher selectivity, especially stronger inhibitory effects on common EGFR mutations (such as EGFR T790M mutation). This superior selectivity allows osimertinib to more effectively inhibit tumor growth while reducing adverse effects on normal cells.

Clinical studies have shown that osimertinib has significant efficacy in the treatment of EGFR T790Mpositive advanced NSCLC patients. It not only extends patients' progression-free survival (PFS) but also improves overall survival. In addition, osimertinib generally has less toxic side effects than some other treatment options, allowing patients to better tolerate the treatment.